Table 5.
Cytotoxicity and antiviral activity in HEL cell cultures
| Compound | R | MCCa (μM) | EC50b (μM) |
|||
|---|---|---|---|---|---|---|
| HSV-1 (KOS) | HSV-1 (TK− KOS ACVr) | HSV-2 (G) | Vaccinia virus | |||
| trans-9d |  |
|||||
| (exp. 1) | ⩾100 | 45 | 45 | 45 | 45 | |
| (exp. 2) | ⩾100 | 45 | 45 | >100 | >100 | |
| cis-9d | ||||||
| (exp. 1) | >100 | 50 | 50 | 50 | 45 | |
| (exp. 2) | >100 | 58 | 58 | 58 | >100 | |
| trans-9f |  |
|||||
| (exp. 1) | ⩾100 | 45 | 45 | 45 | 45 | |
| (exp. 2) | ⩾100 | 45 | 45 | >100 | >100 | |
| cis-9f | ||||||
| (exp. 1) | >100 | >100 | >100 | 58 | 50 | |
| (exp. 2) | >100 | >100 | >100 | 100 | 58 | |
| Brivudin | ||||||
| (exp. 1) | >250 | 0.01 | 2.0 | 146 | 17 | |
| (exp. 2) | >250 | 0.05 | 10 | 250 | 22 | |
| Cidofovir | ||||||
| (exp. 1) | >250 | 1.0 | 1.2 | 1.0 | 22 | |
| (exp. 2) | >250 | 2.0 | 2.0 | 1.5 | 22 | |
| Acyclovir | ||||||
| (exp. 1) | >250 | 0.2 | 2.0 | 0.08 | >250 | |
| (exp. 2) | >250 | 0.2 | 2.0 | 0.2 | >250 | |
| Ganciclovir | ||||||
| (exp. 1) | >100 | 0.03 | 0.8 | 0.03 | >100 | |
| (exp. 2) | >100 | 0.02 | 0.5 | 0.03 | >100 | |
a
Minimum cytotoxic concentration that causes a microscopically detectable alternation of cell morphology.
b
Effective concentration that is required to reduce virus-induced cytopathogenicity by 50%.